Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Beroni Group","sponsor":"Beroni Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beroni Group teams up with Tianjin University for COVID-19 treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Beroni Group","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beroni Group Advances Research and Development of Medical Solution for Coronavirus (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Beroni Group","sponsor":"Tianjin University in China","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beroni Group Has Successfully Constructed and Purified 24 Types of Nanobodies for Detection and Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Beroni Group","sponsor":"GenScript Biotech Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beroni Group Collaborates with Genscript Biotech Corporation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Beroni Group

    Menu

    Beroni Group

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Beroni Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Beroni Group Has Successfully Constructed and Purified 24 Types of Nanobodies for Detection and Treatment of COVID-19

              Details:

              The scientists have successfully established a prokaryotic expression and purification system for nanobodies in vitro. For 8 N-protein nanobodies, the nanobody expression vectors have been constructed, and the antibodies purified.

              Lead Product(s): nanobody

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Tianjin University in China

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 04, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Beroni Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Beroni Group Collaborates with Genscript Biotech Corporation

              Details:

              Genscript to provide services to Beroni: Perform pseudovirus neutralization assay with candidate antibody Production and characterization of humanized antibodies and Using PML and FASEBA to carry out affinity maturation and purification of the antibodies.

              Lead Product(s): Nanobodies

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Recipient: GenScript Biotech Corporation

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration August 04, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Beroni Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Beroni Group Advances Research and Development of Medical Solution for Coronavirus (COVID-19)

              Details:

              Beroni Group's development of a medical solution using nanobody technology for the novel coronavirus with Tianjin University in China has advanced into cytological experiments in March 2020.

              Lead Product(s): COVID-19 drug

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 13, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Beroni Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Beroni Group teams up with Tianjin University for COVID-19 treatment

              Details:

              A team of scientists from Tianjin University and from Beroni Group is working to develop rapid test and treatment of COVID-19 caused by SARS-CoV-2 infection using nanobody-based technology.

              Lead Product(s): Nanobased antibody therapy

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Recipient: Tianjin University

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 20, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY